STOCKS TELEGRAPH

Author: ST Staff

  • What Caused The APLT Stock To Rise Afterhours?

    What Caused The APLT Stock To Rise Afterhours?

    Applied Therapeutics Inc. (APLT) was up 4.32% in after-hours trading at $22.70. Regular session trading saw APLT stock decreased -12.15% or $3.00. APLT stock fluctuated between $21.6162 and $25.00 during trading. It was 0.21 million shares that changed hands on the day, exceeding the firm’s daily volume for the past 50 days, which was 0.1 million shares, and exceeding its average daily volume for the year to date, which is 0.12 million.

    APLT stock has gained -38.43% in the past 12 months, and it has lost -8.42% in the past week. APLT stock has lost -2.42% over the last six months, and it has increased 18.84% over the last three months. Stocks in APLT have returned -1.14% so far this year. After falling 12% in regular sessions and becoming part of Russell index, APLT stock recovered in extended trades.

    When did APLT become part of the index?

    Biopharmaceutical company Applied Therapeutics develops novel drug candidates for indications with a high unmet medical need against validated molecular targets. APLT’s lead compound candidate AT-007 is an Aldose Reductase Inhibitor (ARI) that targets metabolic diseases of the CNS including Galactosemia, SORD Deficiency, PMM2-CDG and other rare metabolic diseases.

    At the same time, APLT is developing AT-001, a novel potent ARI, for the treatment of Diabetic Cardiomyopathy, or DbCM, a fatal form of heart fibrosis. AT-003 will allow APLT in treatment for Diabetic retinopathy to cross the back of the eye when taken internally, in addition to novel dual PI3K inhibitors for the treatment of orphan oncology indications in preclinical development.

    A recent press release from Applied Therapeutics stated that it has joined Russell Microcap Index. After the market closed on June 25, 2021, the reconstituted index took effect and APLT stock added to that. As a member of the Russell Microcap Index, APLT is automatically included in the appropriate growth and value style indices for one year. According to FTSE Russell, market capitalization rankings and style attributes determine membership in its Russell indexes.

    Applied Therapeutics (APLT) announced that the US Food and Drug Administration (FDA) granted AT-007 Fast Track status for treatment of Galactosemia, a rare metabolic disease. APLT’s AT-007 is a systemically-permeable Aldose Reductase inhibitor in development for multiple rare metabolic diseases, including Galactosemia, SORD and PMM2-CDG.

    How APLT will benefit from Fast Track status?

    The Fast Track designation will help Applied Therapeutics (APLT) develop and review drugs for serious conditions that are unmet medically, meaning that its drugs will be available to patients sooner. Fast Track designation for APLT’s clinical programs means that FDA will be able to communicate with the company early and frequently during the regulatory review process.

  • InnSuites (IHT) Stock Stabilized In Extended Trades. How Did That Happen?

    InnSuites (IHT) Stock Stabilized In Extended Trades. How Did That Happen?

    On the last check Monday, InnSuites Hospitality Trust (IHT) fell -0.27% to $7.51 in after-hours trading. InnSuites stock lost -2.33% to close the last session at $7.53. Shares of the IHT were priced between $7.45 and $7.78.

    IHT traded 0.22 million shares, which was less than its daily average of 3.17 million shares over the past 100 days. IHT’s shares have gained 7.88% over the past five days, while they have gained 12.72% over the last month. Dividend yield currently stands at 0.27% for the company.  After releasing financial results for Q1 2021, IHT stock fell.

    IHT: How is it doing?

    InnSuites was listed on the New York Stock Exchange in 1971 and has its headquarters in Phoenix, Arizona. IHT is an unincorporated business in Ohio. Under its InnSuites Hotels name, this trust owns and manages hotels. IHT owns and operates hotels, including marketing and reservation services. The company provides hospitality services to hotels. IHT has been innovating and recognizing hotel membership needs under the brand name “InnSuites” for over 40 years.

    InnSuites yesterday published its quarterly results for the fiscal first quarter 2022.

    • This year’s fiscal first-quarter profit was $157,161, which represents an increase of over $500,000 from the loss of ($352,857) generated in the same period of last year.
    • For the 2022 fiscal first quarter ended April 30, 2021, revenues were approximately $1.4 million, relatively flat from approximately $1.4 million for the same prior year period.
    • Based on basic earnings per share, the company’s profitability reached ($0.01), compared with ($0.04) a year earlier.
    • In addition to the solid start of operations, IHT’s current fiscal year (2021-2022) was able to grow, due in part to the decreased impact of Covid-19.
    • The solid results of IHT in Fiscal Q2 of this year have speeded up.
    • InnSuites specifically, as well as the Travel Industry and the Economy as a whole, are exhibiting all of these positive signs and are continuing to rebound and recover.
    • It was the second consecutive quarter in which the IHT experienced improved economic conditions.
    • Compared to Q2 and Q3 of Fiscal Year 2021, both the first quarter of Fiscal Year 2022 and the fourth quarter of Fiscal Year 2021 showed signs of growth, improvements, and strength.

    50 Years of dividends at IHT:

    Prior to this investment, InnSuites Hospitality Trust (IHT) had made an initial $1 million investment in privately held UniGen Power, Inc. (UniGen), which is developing an innovative clean energy technology with high profit potential.  With the fiscal year ending in 2021, IHT’s uninterrupted, continuous dividend payouts extended to over 50 years. IHT’s Board is expected to continue this impressive record of semi-annual dividend payments in July 2021 and January 2022.

  • SCWorx Corp, (WORX) stock surged in the after hours trading session; here’s why

    SCWorx Corp, (WORX) stock surged in the after hours trading session; here’s why

    In the after-hours trading session, SCWorx Corp. (WORX) stock had risen at last check by 12.57% to trade at the price of $1.88. WORX stock previously closed the session of Monday and gained 2.45% at $1.67. In the past 50 days, the WORX stock volume traded 0.37 million shares, and today traded 0.79 million shares. In the past year up to date, WORX shares have shed by -27.71% and in the past week the stock has moved up by 7.05%. In the past three and six months, the WORX stock has shed -17.73% and has shed -9.87%.

    Find out what all there is to about SCWorx Corp.’s operational framework

    SCWorx Corp. is health information services company from the healthcare industry that specifically focses on providing its clients software solutions relating to health management and business application systems. These services are required by heath care providers like hospitals, clinics, medical research centers and labs. The company has set up its operations in the United States.

    The service and product offerings that the company provides includes repair, maintenance, installation of information system, as well as analysis of big data models through display and statistical operations. The product offerings include various software solutions which includes the virtualized item master file repair, automation of files as well as expansion of work. There is an electronic medical management service that provides records and integrates master management for healthcare providers through integration of their healthcare purchasing monitoring systems.

    WORX stock also provides a module for healthcare providers to manage automation for the administering of care to patients. A completely diverse project that the company provides in its services is the CageTix which is a ticketing platform for the industry of mixed martial arts. SCWorx Corp. has also decided to sell rapid test kits for COVID-19 as well as PPE. The company is based in New York.

    Recent updates and development in SCWorx

    As of June, SCWorx has made some managerial changes and updated their progress on compliance with NASDAQ Listing Standards. WORX stock’s board of directors had made an announcement in which they promoted Tim Hannibal who was the President and Chief Operating Officer of the company to the Chief Executive Officer of the company. Mr. Hannibal has been with the company for almost the past 5 years. Initially, Hannibal was appointed for the role of Chief Revenue Officer in 2016 and has been the CEO and president for 13 years of Software-as-a-Service company known as VaultLogix.

    Compliance with NASDAQ Stock Market listing requirements

    SCWorx also announced that it was focusing on bringing the necessary requirements onto the table which has allowed it to regain compliance with Nasdaq Stock Market for its continued listing requirements. Specifically, the requirements were related to stockholder meetings and periodic reporting.

    The letter was dated 25th May 2021, which officially confirmed the compliance with the NASDAQ listing by adhering to and reporting the Company’s Annual Report requirement on the 10-K for the year that ended 31st December 2021, and then the rest of the deficiencies had been rectified as soon as the company completed its Special Meeting along with Annual Meeting of Stockholders on 24th May 2021.

  • DiamondRock (DRH) Stock Fell 29% Afterhours, Why?

    DiamondRock (DRH) Stock Fell 29% Afterhours, Why?

    The shares of DiamondRock Hospitality Company (DRH) were down -27.81% in after-hours trading at the last check. In Monday’s regular session, DiamondRock stock closed at $9.71, a decline of 3.09 percent. DRH stock volume remained steady at 1.96 million shares, a little higher volume than the average daily volume of 1.67 million shares over the past 50 days.

    Within the past week, DRH shares fell by -4.80%, and the stock has gained 92.28% in the last year. The DRH stock has fallen -6.00% over the past three months, 15.49% during the past six months. The market capitalization of DRH is $2.07 billion, with 211.67 million outstanding shares. Announcing the release date of its financial results has led to a decline in DRH stock.

    When will DRH announce its results?

    DiamondRock is a self-advised real estate investment trust (REIT) with a diversified portfolio of hotels located in leading gateway markets and resort destinations. Over 8,800 rooms are currently available in 29 premium quality hotels owned by DRH. Hotels operated by DRH are both branded hotels under leading global brands and boutique hotels in the lifestyle segment.

    DiamondRock will report financial results for the second quarter of 2021 after the market closes on Thursday, August 5th, 2021.

    • The next day, Friday, August 6th, DRH will host a conference call for investors and other interested parties.
    • The earnings release for DRH, which will be available on DiamondRock’s website in the Investor Relations section, will contain the information to be discussed during the conference call.
    • DRH will facilitate access to the conference call by telephone as well as over the internet.
    • People interested in listening to the call can do so by dialing 844-287-6622.
    • DRH instructed the investor that in order to participate during the webcast, they would need to log on to www.drhc.com 15 minutes prior to the call in order to download the necessary software.
    • Two hours after the live broadcast ends on August 27th, DRH will make a taped rebroadcast of the call available to those unable to listen live.
    • On its website, DRH will make the conference call replay available for one week.

    DRH will pat dividend:

    DiamondRock (DRH) announced earlier this month that its Board of Directors declared a dividend of $0.515625 per share on its Series A Cumulative Redeemable Preferred Stock. Shareholders of record on June 18, 2021 will receive the dividend from DRH on June 30, 2021.

  • Universe Pharmaceuticals Inc. (UPC) Stock Surges Following Progress on Partnership with Kitanihon

    Universe Pharmaceuticals Inc. (UPC) Stock Surges Following Progress on Partnership with Kitanihon

    Universe Pharmaceuticals Inc. (UPC) stock prices were down by 3.93% as of the market closing on June 29th, 2021, bringing the price down to USD$2.93 at the end of the trading day. Subsequent after-market fluctuations have seen the stock surge by 17.23%, bringing it up to USD$3.47.

    Collaboration with Kitanihon

    May 25th, 2021 saw the company announce having entered into a letter of intent for strategic cooperation with Kitanihon Pharmaceutical. UPC plans to strategically collaborate with a Japanese company that specializes in the research, development, manufacturing, and distribution of healthcare products.

    Details of the LOI

    As per the LOI, the partnership will seek to establish a flagship store on global.jd.com, which is a popular e-commerce platform in China that offers imported products. UPC will operate the flagship store and sell Kitanihon’s products as an exclusive distributor. Distribution of KP’s products will span Chinese and Southeast Asian markets through respective international e-commerce channels, with the aim of fostering growth opportunities for both companies.

    Strategic Partnership

    Furthermore, UPC and KP have agreed to collaborate on the establishing of a medical product research and development center, which will be named Universe Hanhe Medical Research Institute Co., Ltd. Scaffolding by favorable policy treatment from the Chinese government, UPC will make use of its R&D capacity and medicinal resources, while KP will utilize its quality control standards and advanced technologies. Together the two will pool resources towards the development of expanding their portfolio of medical products.

    Joint Venture Facility

    According to the LOI, the achievement of specific strategic goals will lead to the collaborative construction of a manufacturing facility in accordance with the market access requirements from Japan’s Pharmaceutical and Medical Devices Agency (PMDA). The companies will collaborate to ensure the facility will be recognized as a qualified foreign manufacturer of pharmaceutical products, as well as facilitate PMDA certification as a Chinese medicine brand.

    About UPC

    UPC is a pharmaceutical producer and distributor in China that specializes in traditional Chinese medicine derivative products. Its target consumer audience is the elderly, with the aim of addressing physical conditions through the aging process and to facilitate the promotion of their general well-being. With the company’s products being sold in 30 provinces in China, it also distributes and sells biomedical drugs, medical instruments, Traditional Chinese Medicine Pieces, and dietary supplements manufactured by third-party pharmaceutical companies.

    Future Outlook for UPC

    Armed with the expanded pool of resources from its ongoing partnership, UPC is poised to capitalize on the opportunities afforded to it and continue its trajectory of success. Current and potential investors are hopeful that management will continue to leverage the resources at their disposal to facilitate significant and sustained increases in shareholder value.

  • BSQUARE Corporation (BSQR) stock surged in the after-market trading session; here’s why

    BSQUARE Corporation (BSQR) stock surged in the after-market trading session; here’s why

    BSQUARE Corporation (BSQR) stock had surged in the after-hours trading session by 12.60% to $2.95 at the last check. BSQR stock previously closed the session on Monday and gained 8.26% at $2.62. The BSQR stock volume traded 0.55 million shares. In the past year up to date, BSQR stock has surged by 72.37%, and in the past week has jumped up by 15.93%. In the past three and six months, the stock has shed -20.36%, and 94.07%.

    What you need to know about BSQUARE Corporation

    BSQUARE Corporation is a software application company that specifically provides software and software related solution as well as engineering services to clients. These services and operations are used to develop, commercialize and sell unique intelligent programs and systems. The BSQR stock operates in North America, Asia as well as Europe. There are two divisions to the company’s portfolio which includes Partner Solutions and Edge to Cloud.

    The clients of the company require solutions to problems of manufacturing and operations of connects devices which is what BSQUARE provides. The company also provides software for the cloud-enablement and interconnection of devices to create an intelligent system. Furthermore, the company sells Internet of Things specifically reselling Windows related products along with Abode and McAfee related system utility software.

    The company also provides licensing agreements, tech support consultancy, support for manufacturing which also include operating system’s administration and installation, IoT configuration, data engineering and professional outsourcing.

    The client base of BSQR stock includes design manufacturers, peripheral and silicon vendors. The company’s origin are from 1994 and is established in Seattle, Washington.

    The recent activities taking place inside the operations and balance sheet of BSQR stock

    The month of June has been relatively quiet for the press news activities and operations-related news. However during this time, the stock of the company is still experiencing its usual trajectory and oscillations this is because behind the stage, there are still previously mentioned prospects that are still relevant for which investors are making trading decisions in a certain stock as well as fundamental analysis.

    The last announcement by BSQUARE is in the month of May where the company announced after two weeks, the financial result of its first-quarter 2021. The company faced a significant loss in its fundamental analysis due to a decrease in the revenue by 10% to $10 million. BSQR stock displayed an increase net loss by $0.7 million to $0.9 million compared to year over year same period. The total cash on hands with BSQUARE had decreased by $2.6 million from December 31, 2020. Furthermore, the EBITDAS of the company also faced a $0.7 million decrease compared to the previous year same period.

    The major reduction in revenue came from the Partner Solutions segment due to the disruption caused by the pandemic. However, there is still good news as the company’s Edge to Cloud segment saw an increase in its revenue which is also due to shift in the work culture to online and cloud stirred by the pandemic disruption. Furthermore, the company made its operations more efficient by cutting down on costs and reducing office costs which lead to decreased total operating expenses.

  • New Senior Investment Group Inc. (SNR) Stock Surges Following Announcement of Acquisition by Ventas

    New Senior Investment Group Inc. (SNR) Stock Surges Following Announcement of Acquisition by Ventas

    New Senior Investment Group Inc. (SNR) stock prices were up by a significant 29.15% shortly after market trading commenced on June 28th, 2021, bringing the price up to USD$8.95 early on in the trading day.

    Buyout Transaction

    June 28th, 2021 saw Ventas Inc. announce its intentions to buy New Senior Investment Group in an all-stock transaction that is valued at roughly USD$2.3 billion. The move will see the healthcare-focused real estate investment trust expand its footprint into the senior housing market. As per the transaction, existing shareholders of SNR will receive 0.1561 shares of newly issued Ventas shares for every share of SNR. The resulting price of each SNR comes out to USD$9.10, representing a significant 31.7% premium.

    Details of the Transaction

    With the deal including USD$1.5 billion in debt, a closing date is expected for the second half of 2021. Ventas has cited the eventual recovery of the senior housing industry in a post-pandemic economy as a major reason for their decision to purchase SNR. The transaction is expected to result in the realizing of between USD$16 million to USD$18 million in annualized corporate synergies.

    Operating Expense Reports

    Operating expenses for the first quarter of 2021 were reported to be 3.2% lower than numbers reported for the same time period of the prior year. This year-over-year difference is largely attributable to reduced spending on occupancy-related expenses and other controllable costs, such as supplies and maintenance. Utilities and insurance expenses were up because of the winter storms earlier in February of 2021 affecting businesses across the United States. Operating expenses stemming from the impact of the pandemic came out to USD$0.3 million, down 46% from the prior year and 45% from the prior quarter.

    NOI Margins

    The first quarter of fiscal 2021 reported an NOI margin of 36.1%, down from the 39.1 reported in the fourth quarter of 2020. The quarter-over-quarter reduction was largely driven by the occupancy declines that have been persistent since the onset of the pandemic, with the February storms further exacerbating the situation. As operators push for occupancy growth, short-term margins are expected to suffer before picking up in the longer run.

    Future Outlook for SNR

    With the company set to be acquired, SNR is poised for the expanded facilities that will be made available to it to drive further growth. Current and potential investors are hopeful that management will continue to leverage the resources at their disposal to facilitate significant and sustained increases in shareholder value.

  • Kymera Therapeutics Inc. (KYMR) stock has surged in the current trading session; find out why

    Kymera Therapeutics Inc. (KYMR) stock has surged in the current trading session; find out why

    In the current trading session, Kymera Therapeutics Inc. (KYMR) stock shares had surged by 3.75% to trade at the price of $46.04 at last check. KYMR stock had previously closed down the session at the share price of $44.38. The KYMR stock volume traded 73906.0 shares, while the average daily volume of KYMR stock trade is 0.4 million shares for the past 50 days. KYMR shares have moved down in the past week by -6.27%. In the past three and six months, the KYMR stock has gained 16.67%, and however shed -44.92% respectively. Furthermore, Kymera Therapeutics Inc. is currently valued in the market at a total of $1.99 billion and has 44.65 million in total outstanding shares.

    Here’s what you need to know about Kymera Therapeutics Inc.

    Kymera Therapeutics is a biopharma and biotech company that specifically focuses on the manufacturing and designing of therapeutics for unmet medical needs. The company’s operational platform is for the discovery and development of treatment against disease-causing proteins through small molecule therapeutics. This small molecule therapeutics have the ability to assist the body’s natural protein degradation tendencies in its system.

    The KYMR stock has programs in its pipeline which include the treatment of immunology-inflammation diseases through the development of its treatment product known as IRAK4 program which is in phase I clinical trial and includes treatment of hidradenitis suppurative, atopic dermatitis and rheumatoid arthritis.

    IRAKMiD program is used for the treatment of MYD88-mutated B cell lymphoma which are diffuse and large. The STAT3 program is being carried out for the hemtologic malignancy cures and solid tumors, along with autoimmune diseases. The company was established in 2015 and is based in Watertown, Massachusetts.

    Kymera Therapeutics has displayed positive interim data for its single dose of KT-474 in phase 1 trial

    One of KYMR stock’s leading candidates included the KT-474 program which has recently displayed positive interim results. The phase 1 trial of the single ascending dose of KT showed that the drug exceeded beyond the 85% target degradation and achieved success within the SAD portion of 90% median degradation at 300mg dose.

    Kymera did not observe any adverse effects during this trial study on any level of the dose. All doses were administered as a single administration. These observations reflected the efficacy and safety of the targeted degradation of protein which also displays proof of mechanism as required by the FDA. This safety and efficacy display has allowed FDA to confide in the proof of mechanism and allow for the uplifting of a partial clinical hold on the Multiple Ascending Dose portion of the Phase 1 trial. Kymera will take full advantage of this access and will also plan to repeat dosing in the next month.

  • Exelixis, Inc. (EXEL) Stock Plummets Following Disappointing Interim Results for COSMIC-312 Clinical Trial

    Exelixis, Inc. (EXEL) Stock Plummets Following Disappointing Interim Results for COSMIC-312 Clinical Trial

    Exelixis, Inc. (EXEL) stock prices were down by a significant 19.46% as of the market opening on June 28th, 2021, bringing the price down to USD$18.86 early on in the trading day.

    COSMIC-312 Trial

    June 28th, 2021 saw EXEL announced that its COSMIC-312 Phase 3 pivotal trial met a primary endpoint, wherein the treatment demonstrated substantial improvement in progression-free survival at the planned primary analysis. The trial is designed to evaluate CABOMETYX in combination with atezolizumab versus sorafenib in patients reporting untreated advanced hepatocellular carcinoma.

    Interim Analysis

    Being conducted concurrently, a prespecified interim analysis for the secondary endpoint of overall survival indicated results that favored a CABOMETYX and atezolizumab combined treatment. The data did not reach statistical significant and the company does not expect a high probability of the final analysis resulting in the reaching of statistical significance. The trial is currently ongoing, with plans to continue through to the final analysis of OS, the results of which are forecasted for early 2022.

    Strength of Combined Treatment

    In the evaluation of the primary endpoint of PFS in the PFS intent-to-treat population, the risk of disease progression or death was 37% lower with CABOMETYX in conjunction with atezolizumab, as compared to treatment with CABOMETYX and sorafenib. The combined treatment’s safety was consistent with existing safety profiles of the individual medicines, with no new safety signals being identified. The company is discussing trial results while strategizing its next steps for regulatory filing with the U.S. FDA.

    Shortcomings of Treatment

    While the combined treatment of CABOMETYX in conjunction with atezolizumab has indicated encouraging results for the reduction of the risk of disease progression or death, it fell short of proving significant improvement in OS as compared to the comparator arm. The company is exploring the data it has generated, identifying factors that contributed to the results, including patient demographics, subsequent anti-cancer therapy, and the effects of the pandemic on the trial.

    Scope of Treatment

    With more than 900,000 new cases of liver cancer being diagnosed around the world annually, 90% of the cases are HCC. HCC is a leading cause of cancer-related fatalities, with forecasts of the disease claiming 1 million lives every year by 2030. It is the fastest-rising cause of cancer-related death in the U.S, with patients having a median survival period of 1-1.5 years.

    Future Outlook for EXEL

    With the recent developments with its highly-anticipated trial, EXEL is poised to capitalize on the opportunities afforded to it in order for it to bounce back stronger than ever. Current and potential investors are hopeful that management will continue to leverage the resources at their disposal to facilitate significant and sustained increases in shareholder value.

  • Is There Any Reason As To Why The PERI Stock Is Expanding Premarket?

    Is There Any Reason As To Why The PERI Stock Is Expanding Premarket?

    Perion Network Ltd. (PERI) shares have gained 11.47% to $20.80 in premarket trading on Monday. Last trading session, Perion stock dropped -1.84% to finish at $18.66. Perion stock witnessed a trading volume of 0.45 million shares, which is below the average daily trading volume for the past 50 days of 0.64 million shares. PERI stock has gained over 12.61% over the last month despite the recent gains of 15.61% over the last five days.

    Since the beginning of the year, the price of PERI stock has increased 46.58 percent. A 48.98 price-to-earnings ratio is being used to value the PERI stock. Moreover, the company’s price to cash flow ratio is 19.03, and its price to sales ratio is 1.76. Since the preliminary second-quarter results were strong, the PERI stock was up.

    How strong has PERI been?

    With its innovative solutions, Perion offers innovative solutions covering all three principal pillars of digital advertising, for brands, agencies, and publishers. PERI’s consolidated platform for Synchronized Digital Branding includes data-driven ad formats in the display domain as well as a powerful social media platform and a branded search network, allowing it to capitalize on changes in marketers’ allocation of digital advertising budgets.

    Perion today released preliminary results for its second quarter of 2021, along with increased revenue and adjusted EBITDA guidance for the full year.

    Preliminary results:

    • Perion’s preliminary revenue for the second quarter was $105 million, compared to $60.3 million for the comparable period last year.
    • According to PERI, the preliminary adjusted EBITDA for the second quarter is $13.5 million, compared to $2.5 million for the same period in 2020.
    • The Hub and Spoke concept, which connects demand and supply sides of the “open internet”, improved PERI’s adjusted EBITA margins through increased efficiencies.
    • PERI’s projected advertising revenue has increased year over year as a result of video advertising and CTV.
    • PERI’s search revenues have also increased as a result of client performance marketing initiatives.
    • Prior to the opening of the financial markets on Tuesday, August 3, 2021, Perion will release its financial results for the second quarter and six months ended June 30, 2021.
    • A conference call will be held by Perion management to discuss the results at 8:30 a.m. ET on that day.

    How PERI excelled?

    Perion (PERI)’s cross-channel diversification strategy took a giant leap forward with a robust start to revenue growth in the Retail Media vertical. As PERI advances in verticalization, it is also gaining market share and establishing long-term partnerships with customers.